Related Experiment Video

Updated: Feb 7, 2026

Evaluation of the Interplay Between the Complement Protein C1q and Hyaluronic Acid in Promoting Cell Adhesion
06:54

Evaluation of the Interplay Between the Complement Protein C1q and Hyaluronic Acid in Promoting Cell Adhesion

Published on: June 15, 2019

6.4K

C1q tumor necrosis factor-related protein 9 in atherosclerosis: Mechanistic insights and therapeutic potential

Xiao-Hua Yu1, Da-Wei Zhang2, Xi-Long Zheng3

  • 1Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, Medical Research Experiment Center, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, Hunan, 421001, China.

Atherosclerosis
|July 30, 2018
PubMed

Insights

C1q tumor necrosis factor-related protein 9 (CTRP9) may protect against atherosclerosis. Lower CTRP9 levels are linked to coronary artery disease, suggesting its therapeutic potential for cardiovascular conditions.

Area of Science:

  • Biochemistry
  • Cardiovascular Biology
  • Metabolic Research

Background:

  • C1q tumor necrosis factor-related protein 9 (CTRP9) is a newly identified adipokine and the closest paralog of adiponectin.
  • The active form, globular CTRP9 (gCTRP9), is released via proteolytic cleavage and circulates as the primary isoform.
  • CTRP9 interacts with AdipoR1 and N-cadherin, modulating key signaling pathways involved in metabolic and vascular functions.

Purpose of the Study:

  • To review the current understanding of CTRP9's role in atherosclerosis.
  • To highlight CTRP9's atheroprotective mechanisms and potential as a therapeutic target for cardiovascular disease.

Main Methods:

  • Review of in vitro and animal model studies investigating CTRP9's functions.
  • Analysis of circulating CTRP9 levels in patients with coronary atherosclerosis disease.

Main Results:

  • CTRP9 levels are significantly reduced in patients with coronary atherosclerosis disease.
  • CTRP9 demonstrates atheroprotective effects by mitigating inflammation, foam cell formation, endothelial dysfunction, and insulin resistance.
  • CTRP9 influences vascular smooth muscle cell behavior, including differentiation, proliferation, and migration.

Conclusions:

  • CTRP9 plays a significant role in protecting against atherosclerosis through multiple mechanisms.
  • CTRP9 represents a promising novel therapeutic target for cardiovascular diseases, particularly atherosclerosis.

Keywords:
AdipoR1AdiponectinAtherosclerosisCTRP9N-cadherin

More Related Videos

Quantification of Immunostained Caspase-9 in Retinal Tissue05:18

Quantification of Immunostained Caspase-9 in Retinal Tissue

Published on: July 25, 2022

1.8K
Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model06:12

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

7.7K

Related Concept Videos

Necrosis01:16

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
6.6K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
239
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
574
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
487
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
327
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
430